Meeting Minutes:

Joyce presented the overall approach of constructing the model by starting with
the HL7 CG Domain Information Model (Visio model used to develop messages) and
integrating the concepts from about 12 NCI models.

Joyce presented an overview of a rough draft of the Clinical Genomics Model.
She emphasized the goals of producing a model the scientific community can understand and that the Clinical Genomics team can use to validate that all the proper concepts
are included within the HL7 messages.  Some questions/comments were voiced by the team as follows:

1.  Michael thinks that Genetic Loci should remain in the model since it is associated
    with the biological underpinning.  However the team felt more details are needed 
    regarding its role in the model.  Michael, Ted and Juli will query scientists in order 
    to describe the actual role.  It was proposed that Genetic Loci might be used to 
    describe Genotype or perhaps the biological pathway.
2.  There are a couple of classes (e.g. Large Deletion, Large Duplication) that have been 
    identified as associated with non-locus.  These are based on methods (e.g. by 
    microscope)  that can detect some very prevalent or coarse observations. However, 
    these cannot be attributed to specific genes, hence the non-locus.  Jennifer suggested 
    there are more categories to add such as translocation.  Joyce will look at HGVS 
    (suggested by Michael) for more examples.
3.  Fred suggested breaking out the Transportation Class into subclasses (Shipment and 
    Receiving).  Joyce will modify the model and review with the team to see if changing 
    the classes help in facilitating understanding of the underlying data.
4.  In general the team was requested to look at the definitions and data representation 
    to ensure scientific concepts were properly represented.
5.  Juli Klem advised me that the NCI has just kick-started a project to consolidate their 
    models (something very similar to what we are doing with the CG DAM) so we will 
    be in close collaborations possibly meeting within a week or two.


New Use Cases:

Michael gave an overview of a new scenario which he will document and present in a future meeting in more detail.  The scenario represents a clinical trial with third party who handles the samples.  The samples are sent to a lab and the results of the testing done by the lab are sent back to the provider with no bubbled up data.  The data is then used
to perform analysis in-house.

Juli presented a brief over view of a second use case. A study performs genetic testing in
order to develop cohorts (sub-population of subjects) that are then assigned to treatment
arms in the trial.

We determined to use the concept "molecular assay" to refer to the different modalities such as Genotyping, Gene Expression, and Proteomics etc.

Michael brought up the topic of the RPS (Regulated Product Submission) message and how that would work with the Genetic data. I thought this could be a good topic for us
at a future call (either the Gene Expression or general CG call). We could request 
someone from RPS to come and talk with us.  Phil can also give us his perspective
since he is very knowledgeable having modeled the CTLAB message.

Post Meeting Update:

Mollie submitted clincal care use case.